title: Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.
abstract: We have compared the immunogenicity profile of a recombinant lipoprotein outer-surface protein A (OspA) Lyme disease vaccine administered on schedules of 0, 1, and 6 months (group 1) or 0, 1, and 12 months (group 2) to 800 healthy subjects, aged 15-50 years. One month after the second dosing, geometric mean titers of IgG antibodies to OspA were 1,309 ELISA units (EL.U)/mL in group 1 and 1,404 EL.U/mL in group 2. One month after the third dosing, the titers were 7,205 EL.U/mL and 10,659 EL.U/mL, respectively. Using bioequivalence methodology, we showed that the two vaccination schedules elicit an equivalent immune response 1 month after administration of dose 3: at that point, 91%-93% of all subjects had titers > or =1,400 EL.U/mL, proposed to be protective for one tick season. The vast majority of local and systemic symptoms were mild to moderate and of limited duration. The 0, 1, and 6 months vaccination schedule is a viable alternative to the 0, 1, and 12 months schedule and can provide protection against Lyme disease during one tick season.
authors.affiliation: SmithKline Beecham Biologicals, Rixensart, and Clinique Notre-Dame de Grâce, Gosselies, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Van Hoecke
authors.forename: E
authors.initials: E
authors.lastname: Lebacq
authors.forename: J
authors.initials: J
authors.lastname: Beran
authors.forename: D
authors.initials: D
authors.lastname: Parenti
mesh_terms: D000293:Adolescent; D000328:Adult; D000954:Antigens, Surface / Q000008:administration & dosage*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008074:Lipoproteins; D008297:Male; D008875:Middle Aged; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein; D014614:Vaccines, Synthetic